Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
Do you prefer using echocardiographic guided or SmartAssist guided help for Impella repositioning, and why?
Related Questions
What is your preferred P2Y12 inhibitor to use upstream of STEMI cases, if you decide to administer an agent before proceeding to the cath lab?
How would you proceed with V-A ECMO cannulation (Venous cannula) on a patient with massive PE who has an IVC filter with high thrombus burden?
Would you consider an inpatient Mitraclip for patients with severe MR and severely reduced LVEF who have been turned down/high risk for surgery if there were ongoing challenges with afterload reduction and transitioning to intermittent dialysis due to recurrent flash pulmonary edema?
Would you recommend normal saline for pre- and post-LHC hydration in patients with CKD stage III to IV with reduced LV systolic function, and if so, what is a reasonable amount of volume?
For SVG graft stenting, do you consider routinely embolic protection devices (EPD), and do you factor lesion location (prox vs distal) for decision making?
When pursuing complex PCI of the RCA (especially when lesion preparation is required), when do you consider placing a transvenous pacemaker in anticipation of conduction abnormalities?
How do you approach revascularization in patients over 75 years with NSTEMI, given recent evidence from the SENIOR-RITA trial that an invasive strategy does not significantly reduce cardiovascular events compared to a conservative strategy?
What techniques do you use in the lab to reduce the amount of contrast that needs to be used in patients with CKD?
What has been your approach to minimizing the risk of vascular complications when placing Impella support devices?
Do you recommend transitioning from ticagrelor-aspirin DAPT to ticagrelor monotherapy after 1 month in patients with acute coronary syndrome and average bleeding risk post-PCI to reduce the risk of bleeding?
